Tesaro Inc (TSRO) 29.05 $TSRO
Nasdaq stocks posting largest percentage increases
AP - Mon May 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why TESARO, Kandi Technologies, and Pinnacle Foods Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon May 12, 4:15PM CDT
Important economic data was again as scarce as it could be on a Monday, but that didn't seem to matter much to the broad-based S&P 500 , which surged to a record close. The culprit behind today's decisive move higher was another weekend...
What Fueled TESARO Inc. Shares' 20% Mega-Surge Today
Alex Planes, The Motley Fool - Motley Fool - Mon May 12, 1:45PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of TESARO are trading about 22% higher today...
Why Tesaro (TSRO) Stock Is Surging Today
at The Street - Mon May 12, 1:11PM CDT
Tesaro (TSRO) surged Monday after the biopharmaceutical company announced positive top-line results from the third and final Phase 3 trial of rolapitant.
OPKO Licensee TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant
Business Wire - Mon May 12, 10:20AM CDT
--Achieved Key Secondary Endpoints of CR in the Acute and Overall Periods
Monday’s Top Health Care Stories: Tesaro, Alnylam, Allergan, and Valeant
Leo Sun, The Motley Fool - Motley Fool - Mon May 12, 8:11AM CDT
Let's look at four stocks -- Tesaro , Alnylam Pharmaceuticals , Allergan , and Valeant Pharmaceuticals -- that could all loom large in health-care headlines this Monday morning. Tesaro reports positive phase 3 results for...
TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant
GlobeNewswire - Mon May 12, 6:30AM CDT
-- Achieved Primary Endpoint of Complete Response (CR) in the Delayed Period (24 to 120 Hours) Following Initiation of Chemotherapy
Biotech of the Week: Opko Health Inc.
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:21PM CDT
Opko Health is the biotech of the week for the Fool's biotech-focused show, Biotech Banter . Of course, "biotech" is a bit of a stretch with Opko, because it's working on both diagnostics and therapeutics. On the diagnostics side, Opko Health is...
Should You Buy Tesaro After Its Earnings Miss?
Leo Sun, The Motley Fool - Motley Fool - Fri May 02, 8:30AM CDT
Tesaro , a development-stage biotech, reported its first-quarter earnings on April 30. Tesaro reported a net loss of $49.8 million, or $1.43 per share -- a steep drop from the loss of $18.9 million, or $0.66 per share, it posted in the...
TESARO's (TSRO) CEO Lonnie Moulder on Q1 2014 Earnings - Call Transcript
at The Street - Thu May 01, 5:17PM CDT
TESARO Inc. (TSRO) Q1 2014 Earnings Conference Call - April 29, 2014 4:15 PM ET
TESARO to Present at the Deutsche Bank Securities 39th Annual Health Care Conference
GlobeNewswire - Thu May 01, 7:13AM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Dr. Mary Lynne Hedley, President of TESARO, will present at the Deutsche Bank Securities 39 Annual Health Care Conference on Wednesday, May 7, 2014 at 1:30 p.m. Eastern time at the InterContinental Hotel Boston.
TESARO Announces First-Quarter 2014 Operating Results
GlobeNewswire - Wed Apr 30, 3:12PM CDT
-- Oral Rolapitant New Drug Application on Track for Submission to U.S. FDA in Mid-2014
TESARO to Announce First Quarter 2014 Financial Results on April 30, 2014
GlobeNewswire - Wed Apr 16, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its first quarter 2014 financial results on Wednesday, April 30, 2014, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on April 30, 2014 to discuss the Company's results in greater detail.
Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director
GlobeNewswire - Mon Apr 14, 3:57PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Lynne Hedley, Ph.D. as a director of Receptos. Dr. Hedley will serve as a Class I director with a term of office expiring and to be renewed at the 2014 annual meeting of stockholders. Dr. Hedley will also serve as a member of the Board's Nominating and Corporate Governance Committee.
Is Biotech in a Bubble? The Bear Case Explained
Chris Ahlstrand, The Motley Fool - Motley Fool - Fri Apr 04, 8:30AM CDT
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not been seen in quite some time in the space. So is...
TESARO Announces Data Presentations At 2014 AACR Annual Meeting
GlobeNewswire - Wed Apr 02, 8:43AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that two posters highlighting its niraparib and immuno-oncology programs will be presented at the American Association of Cancer Research (AACR) meeting, which will take place April 5-9, 2014 in San Diego, California.
Why 2014 May Be a Big Year for Opko Health, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 9:27PM CDT
Philip Frost has never been shy about backing his investments. Frost, the former founder of IVAX , and Chairman of generic heavyweight Teva Pharmaceuticals , has big stakes in a variety of emerging health-care companies. However, out of all his...
Myriad Genetics Inks HRD Alliance with Tesaro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:00PM CDT
Recently Myriad Genetics entered into a companion diagnostics research collaboration with pharmaceutical major Tesaro.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 26, 4:20PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Nasdaq stocks posting largest percentage increases
AP - Mon May 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why TESARO, Kandi Technologies, and Pinnacle Foods Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon May 12, 4:15PM CDT
Important economic data was again as scarce as it could be on a Monday, but that didn't seem to matter much to the broad-based S&P 500 , which surged to a record close. The culprit behind today's decisive move higher was another weekend...
What Fueled TESARO Inc. Shares' 20% Mega-Surge Today
Alex Planes, The Motley Fool - Motley Fool - Mon May 12, 1:45PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of TESARO are trading about 22% higher today...
Why Tesaro (TSRO) Stock Is Surging Today
at The Street - Mon May 12, 1:11PM CDT
Tesaro (TSRO) surged Monday after the biopharmaceutical company announced positive top-line results from the third and final Phase 3 trial of rolapitant.
OPKO Licensee TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant
Business Wire - Mon May 12, 10:20AM CDT
--Achieved Key Secondary Endpoints of CR in the Acute and Overall Periods
Monday’s Top Health Care Stories: Tesaro, Alnylam, Allergan, and Valeant
Leo Sun, The Motley Fool - Motley Fool - Mon May 12, 8:11AM CDT
Let's look at four stocks -- Tesaro , Alnylam Pharmaceuticals , Allergan , and Valeant Pharmaceuticals -- that could all loom large in health-care headlines this Monday morning. Tesaro reports positive phase 3 results for...
TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant
GlobeNewswire - Mon May 12, 6:30AM CDT
-- Achieved Primary Endpoint of Complete Response (CR) in the Delayed Period (24 to 120 Hours) Following Initiation of Chemotherapy
Biotech of the Week: Opko Health Inc.
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:21PM CDT
Opko Health is the biotech of the week for the Fool's biotech-focused show, Biotech Banter . Of course, "biotech" is a bit of a stretch with Opko, because it's working on both diagnostics and therapeutics. On the diagnostics side, Opko Health is...
Should You Buy Tesaro After Its Earnings Miss?
Leo Sun, The Motley Fool - Motley Fool - Fri May 02, 8:30AM CDT
Tesaro , a development-stage biotech, reported its first-quarter earnings on April 30. Tesaro reported a net loss of $49.8 million, or $1.43 per share -- a steep drop from the loss of $18.9 million, or $0.66 per share, it posted in the...
TESARO's (TSRO) CEO Lonnie Moulder on Q1 2014 Earnings - Call Transcript
at The Street - Thu May 01, 5:17PM CDT
TESARO Inc. (TSRO) Q1 2014 Earnings Conference Call - April 29, 2014 4:15 PM ET
TESARO to Present at the Deutsche Bank Securities 39th Annual Health Care Conference
GlobeNewswire - Thu May 01, 7:13AM CDT
TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Dr. Mary Lynne Hedley, President of TESARO, will present at the Deutsche Bank Securities 39 Annual Health Care Conference on Wednesday, May 7, 2014 at 1:30 p.m. Eastern time at the InterContinental Hotel Boston.
TESARO Announces First-Quarter 2014 Operating Results
GlobeNewswire - Wed Apr 30, 3:12PM CDT
-- Oral Rolapitant New Drug Application on Track for Submission to U.S. FDA in Mid-2014
TESARO to Announce First Quarter 2014 Financial Results on April 30, 2014
GlobeNewswire - Wed Apr 16, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its first quarter 2014 financial results on Wednesday, April 30, 2014, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on April 30, 2014 to discuss the Company's results in greater detail.
Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director
GlobeNewswire - Mon Apr 14, 3:57PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Lynne Hedley, Ph.D. as a director of Receptos. Dr. Hedley will serve as a Class I director with a term of office expiring and to be renewed at the 2014 annual meeting of stockholders. Dr. Hedley will also serve as a member of the Board's Nominating and Corporate Governance Committee.
Is Biotech in a Bubble? The Bear Case Explained
Chris Ahlstrand, The Motley Fool - Motley Fool - Fri Apr 04, 8:30AM CDT
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not been seen in quite some time in the space. So is...
TESARO Announces Data Presentations At 2014 AACR Annual Meeting
GlobeNewswire - Wed Apr 02, 8:43AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that two posters highlighting its niraparib and immuno-oncology programs will be presented at the American Association of Cancer Research (AACR) meeting, which will take place April 5-9, 2014 in San Diego, California.
Why 2014 May Be a Big Year for Opko Health, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 9:27PM CDT
Philip Frost has never been shy about backing his investments. Frost, the former founder of IVAX , and Chairman of generic heavyweight Teva Pharmaceuticals , has big stakes in a variety of emerging health-care companies. However, out of all his...
Myriad Genetics Inks HRD Alliance with Tesaro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:00PM CDT
Recently Myriad Genetics entered into a companion diagnostics research collaboration with pharmaceutical major Tesaro.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 26, 4:20PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
